Copyright © Inderes 2011 - present. All rights reserved.

Aiforia Technologies

1.80 EUR

0.00 %

2,185 following
Corporate customer

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

0.00 %
-1.64 %
-27.91 %
-22.96 %
-35.20 %
-53.38 %
-55.79 %
-
-64.53 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
60.48M EUR
Turnover
14.42K EUR
P/E (adj.) (26e)
-7.25
EV/EBIT (adj.) (26e)
-7.49
P/B (26e)
4.47
EV/S (26e)
13.38
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.40 EUR
Updated
08.03.2026
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 09.03.2026

Latest extensive report

Released: 24.04.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
2.4
2026

General meeting '26

28.8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Yes, this will turn out well. The stock is at an ATL (all-time low), hyper-scaling years are about to begin, and the company is number one in market position, at least in Europe. Since the FDA in the USA has been stingy with these permits, no one there is ahead either, in the segment...
3/24/2026, 6:25 PM
by Puutaheinää
18
Proscia Proscia Raises $50M To Advance AI-Driven Pathology And Deliver The Future Of... Proscia®, a software company leading pathology’s transition to digital and AI, has secured $50M in funding, bringing its total raised to $130M. This investment follows Proscia’s record-breaking...
3/25/2026, 5:03 AM
by Salvelinus
16
At least here, everything is in order, and the company is progressing very nicely after small delays. Market leader, best products, excellent partners, and a patent is being sought for the foundation engine, meaning there’s a small moat. Margins will be very crisp in the future; ...
3/24/2026, 7:22 PM
by Jekkku
15
Here’s a bit of hype from an outsider about USCAP. LinkedIn #uscap2026 #digitalpathology #computationalpathology #medicalai... We’re still acting like annotation is the bottleneck. For a long time, it was. Training a good image analysis model meant hundreds or thousands of annotations...
3/23/2026, 7:59 AM
by Puutaheinää
12
In a slightly different position in that digital pathology pipeline, but a small company like Aiforia, only with a valuation in the hundreds of millions. They validate the entire pipeline, and Aiforia has an excellent market position and technological leadership, with its moats. ...
3/25/2026, 8:05 AM
by Puutaheinää
9
Aiforia is recruiting an executive leader for European sales. They really emphasize in bold that the person must be UK-based. What does Aiforia have in the UK that warrants such a clear restriction? Hasn’t it been somewhat on the sidelines until now, at least in clinical cases? Aiforia...
2 hours ago
by Puutaheinää
8
https://www.youtube.com/@dr.aleksdigitalpathology/videos There you’ll find all sorts of interesting things from the field of pathology, and he seemed to have visited Aiforia’s booth, so something new is probably coming soon. I really feel like this will turn out well if we just wait...
3/24/2026, 6:04 PM
by Salvelinus
8
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.